Raxibacumab
Raxibacumab (pronounced as rax-i-bac-u-mab) is a monoclonal antibody that was developed for the treatment and prevention of inhalational anthrax, a life-threatening illness caused by the bacterium Bacillus anthracis.
Etymology
The name "Raxibacumab" is derived from parts of the phrase "Bacillus anthracis immunoglobulin monoclonal antibody".
Usage
Raxibacumab is used in conjunction with appropriate antibiotic therapy for the treatment of inhalational anthrax. It is also used for prophylaxis when alternative therapies are not available or not appropriate.
Mechanism of Action
Raxibacumab works by binding to the protective antigen (PA) component of the lethal toxin produced by Bacillus anthracis. This prevents the toxin from entering and affecting the cells, thereby neutralizing its harmful effects.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Anthrax: A serious disease caused by Bacillus anthracis that affects both animals and humans.
- Bacillus anthracis: The bacterium that causes anthrax.
- Immunoglobulin: A protein produced by plasma cells and lymphocytes and characteristic of these types of cells.
- Antibiotic: A type of antimicrobial substance active against bacteria.
See Also
External links
- Medical encyclopedia article on Raxibacumab
- Wikipedia's article - Raxibacumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski